Drugs / DOTA-biotin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00988715 | Apr 2010 → Jan 2015 | acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts +2 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOTA-biotin | “indium In 111(111In)-DOTA-biotin IV on day -20” NCT00988715 ↗ |
| Modality | Other / unclassified | “radiolabeled DOTA-biotin” NCT00988715 ↗ |
| Route | Intravenous | “indium In 111(111In)-DOTA-biotin IV on day -20” NCT00988715 ↗ |